KalVista Pharmaceuticals focuses on developing oral medicines, particularly for managing hereditary angioedema.
KalVista Pharmaceuticals has raised $125.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in September 2025.
KalVista Pharmaceuticals's investors include RA Capital Management, Novo Holdings, Venrock, Longwood Fund, SV Health Investors.
KalVista Pharmaceuticals is headquartered in Cambridge, United States.
KalVista Pharmaceuticals focuses on developing oral medicines, particularly for managing hereditary angioedema.
KalVista Pharmaceuticals is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"KalVista Pharmaceuticals — Funding & Investors." VCBacked, September 24, 2025, https://www.vcbacked.co/company/kalvista-pharmaceuticals. Accessed July 27, 2026.
VCBacked. (2025). KalVista Pharmaceuticals — Funding & Investors. Retrieved July 27, 2026, from https://www.vcbacked.co/company/kalvista-pharmaceuticals
{{cite web |title=KalVista Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/kalvista-pharmaceuticals |website=VCBacked |access-date=July 27, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated